Eckstein Fritz
Max-Planck-Institut für experimentelle Medizin, Göttingen, Germany.
Trends Biochem Sci. 2005 Aug;30(8):445-52. doi: 10.1016/j.tibs.2005.06.008.
RNA interference (RNAi) - inhibition of gene expression by small, non-coding RNAs [small interfering RNAs (siRNAs) or microRNAs (miRNAs)] - has changed our view of regulation of expression dramatically. The application of siRNAs for both functional analysis of genes and medication raises several questions. These include the design of the double-stranded oligonucleotides, their preparation and introduction into cells or animals either as chemically synthesized entities or as transcripts from a suitable vector. Delivery of the oligonucleotides, choice of vector, chemical modification to stabilize against nucleases and avoidance of side effects (e.g. stimulation of interferons) are major challenges. Work to identify the multiple targets of miRNAs is still in its infancy, and a clear distinction between siRNAs and miRNAs is difficult in some instances. Moreover, transcriptional silencing by RNAi is poorly understood; it is evident that the siRNA machinery is involved but the details await clarification. Given the multitude of interactions of the small non-coding RNAs revealed so far, we should be prepared to encounter, as yet, undiscovered interactions and mechanisms.
RNA干扰(RNAi)——由小的非编码RNA[小干扰RNA(siRNA)或微小RNA(miRNA)]抑制基因表达——极大地改变了我们对基因表达调控的看法。将siRNA应用于基因功能分析和药物治疗引发了几个问题。这些问题包括双链寡核苷酸的设计、其制备以及作为化学合成实体或合适载体的转录本导入细胞或动物体内。寡核苷酸的递送、载体的选择、针对核酸酶进行稳定化的化学修饰以及避免副作用(如刺激干扰素)是主要挑战。确定miRNA多个靶标的工作仍处于起步阶段,并且在某些情况下难以明确区分siRNA和miRNA。此外,RNAi介导的转录沉默了解甚少;显然siRNA机制参与其中,但具体细节仍有待阐明。鉴于目前已揭示的小非编码RNA的众多相互作用,我们应该做好准备去面对尚未发现的相互作用和机制。